New startup ideas · Health and bio · Healthcare and bio
startup idea
Corelane
A spot market for wet-lab experiments that software agents can order by API.
Corelane is a marketplace where pharma and AI-bio R&D teams buy idle bench and instrument time from academic core facilities, contract labs and instrument-rich startups.
- Marketplace
- Enterprise
- $100B+ market
- Creates a new category
- US first
4/5
venture judge
1
similar startups, last 2 years (28 all-time)
97%
of 4 nearest real companies still alive
yes
1 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$1,200 · 5 weeks · 27 prospects
Prove both sides at once: 5 core facilities will quote fixed external prices and 5 AI-bio teams will prepay escrowed experiment orders brokered by hand, for under $1,500 in 5 weeks
1Focus group: who and where
Demand: the founder or lead scientist at a US seed-stage AI-bio company under 15 people that needs mass spec, cryo-EM or binding assay data monthly but cannot justify the instrument. Supply: the director of a university core facility whose mass spec or cryo-EM calendar shows visible idle blocks and who already runs an external rate card
where to find 27 · Demand: the YC company directory filtered to bio and the Bits in Bio Slack, plus LinkedIn Sales Navigator filtered to Biotechnology, 1-15 employees, US, keyword protein or proteomics. Supply: the ABRF (Association of Biomolecular Resource Facilities) member directory and the public core-facility pages of the 20 largest US research universities, which list instruments, external rates and contact emails; 15 buyers and 12 directors reachable in a week
2Sell first, build later
A fixed-price, fixed-turnaround experiment from a named US facility, ordered from a one-page catalog, payment held in escrow and released on delivery of data in the specified format, first orders running within 2 weeks of payment
the ask · $500 to $3,000 per experiment depending on instrument, with Corelane keeping a 15 percent spread; $2,000 prepaid escrow balance for repeat buyers
a real yes · A real yes is money in escrow before a sample ships, or a prepaid balance. A core director saying 'we have idle time' without accepting a live order, and a buyer saying 'we would definitely use this' without funding an order, count for nothing
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Core director supply calls
$100 · 10 days
Call 12 core facility directors from the ABRF directory. Ask three things: current external rate, real idle hours per month, and what university accounting and IP review require before an external for-profit order can run. This attacks the card's stated risk first, before any demand work.
keep going if · 5 of 12 can accept an external paid order within 2 weeks under an existing rate card, without a new master agreement
2. Fake-door priced assay catalog
$300 · 10 days
Publish a one-page catalog of 8 normalized offerings (for example LC-MS proteomics run, SPR binding panel, cryo-EM screening session) each with a fixed price, a turnaround in days and a defined data deliverable, built from the 5 willing facilities' real rates plus 15 percent. Post in Bits in Bio and email the 15 demand-side prospects with an order form.
keep going if · 8 order-form submissions with a named assay and a real sample described within 14 days
3. Concierge escrowed order brokering
$800 · 21 days
For each submission, take payment into escrow up front (Stripe invoice held until data delivery), place the order with the matched core facility by hand, chase the run, and deliver the data in the promised format with a quality note. The founders are the matching engine and the schema; no marketplace code exists.
keep going if · 5 orders prepaid into escrow and 4 delivered on the quoted turnaround, with Corelane keeping a 15 percent spread
4. Repeat-order commitment
$0 · 10 days
Within a week of each delivery, offer the buyer a monthly experiment budget: prepay $2,000 into an escrow balance that draws down against future catalog orders at a 10 percent discount. Tests whether this is a channel or a one-off favor.
keep going if · 3 of 5 first buyers prepay a $2,000 balance
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$2,000
per prospect, refundable
how · Full order value prepaid into escrow via Stripe invoice per experiment, released to the facility on data delivery; repeat buyers sign a one-page terms sheet and prepay a $2,000 drawdown balance set up: Stripe Invoicing ↗
what it reserves · A guaranteed instrument slot at the quoted turnaround, the locked catalog price, and the 10 percent repeat-buyer discount
refund · Escrow refunded in full within 5 business days if the facility misses the quoted turnaround by more than 50 percent or the data fails the specified format
target · 5 escrowed orders from 15 buyer prospects and 3 prepaid $2,000 balances within 35 days
Go: build it if
5 or more willing facilities, 5 or more escrowed orders delivered at a 15 percent spread, and 3 or more prepaid repeat balances: both sides transact at posted prices and the spread supports a marketplace
Kill: stop if
Fewer than 3 of 12 facilities can take an external order within 2 weeks (the supply risk on the card is confirmed and the model dies regardless of demand), or fewer than 3 of 15 buyers fund an escrowed order, or delivered turnarounds run more than double the quote
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
84
Idea Score, 0-100 · raw 51.3 x 1.64
Warm
competition: more crowded than 20% of ideas · headwind x0.90
+0.8
government priorities, secondary (1 matching grants)
Trend
57
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)23
- Rounds announced 2025+ in the sector55
- Sector direction (live batch)100
- 2026 trend analyst50
Demand
52
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain25
100x potential
60
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge75
- Market size axis100
- Moat axis80
- Neighbours still alive6
- Technologist judge25
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were spot, wet-lab, experiments, order, marketplace, pharma, ai-bio, buy.
The idea in full
- What
- Corelane is a marketplace where pharma and AI-bio R&D teams buy idle bench and instrument time from academic core facilities, contract labs and instrument-rich startups. Every listing is normalized into a machine-readable protocol schema with a price, a turnaround and a data format, so a research team or its automated planner can order a binding assay, a cryo-EM session or a proteomics run the way it orders compute. Corelane owns the schema, the escrow and the quality history; it owns no labs.
- Why now
- The 2026 cohort is full of teams whose product is experiment throughput rather than a drug: Omanta (yc S26) pitches a research lab for one, 10x Science (yc W26) an AI-native platform for protein characterization and Rasyn (yc S26) a general intelligence for chemistry, and 126 new companies entered this cluster in 2024 alone, all of them buying bench time from someone.
- Wedge: first customer and entry point
- Ten US university core facilities with visible idle time on mass spec and cryo-EM, matched to the 30-odd seed-stage AI-bio teams in this cluster who cannot justify buying the instrument.
- Path to 100x
- Global pharma R&D spend is above $100B a year and a large share is outsourced experiment by experiment through relationship sales with no posted price; a marketplace that becomes the default API surface for ordering experiments creates the category and takes a fee on flow. Exclusive listing deals with the highest-value instrument sites give a distribution moat, and once agents are wired to one protocol schema, switching means rewriting the planner.
- Ceiling
- Pharma keeps buying experiments through master service agreements with three preferred CROs, leaving Corelane the long tail of small orders and a take rate too thin to reach $1B.
- Closest real companies, as the generator saw them
- Harbor is an AI-native CRO that runs trial operations itself; Corelane never delivers the work, it prices and routes it. Omanta automates one team's own lab rather than pooling other people's capacity.
- Main risk
- Core facilities cannot sell externally at speed because of university accounting and IP review, so supply never becomes liquid enough for a spot price.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
4/5
Capital-light marketplace owning the protocol schema that automated planners write against, taking a fee on $100B+ of outsourced experiment flow.
Bootstrapper
3/5
Capital-light and asset-free, but university accounting and IP review make core-facility supply slow to become liquid enough to price.
Operator
2/5
Pharma buys experiments under master service agreements with three preferred CROs, and university accounting blocks the supply side from listing.
Technologist
2/5
Corelane owns no labs, so the protocol schema and escrow are a listing layer any well-funded CRO aggregator rebuilds.
Risk
3/5
Capital-light and unregulated with no lab ownership, but supply depends on university accounting and IP review that can stall listings indefinitely.
trends
3/5
Machine-readable experiment ordering aligns with 2026's agent-to-service procurement turn, but the card's own why-now is only cohort composition, not a dated shift.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (spot, wet-lab, experiments, order, marketplace, pharma, ai-bio, buy): 28 all-time, 1 from the last two years. Same matching as Idea Check.
Move Loot is the most convenient and economical way to buy and sell…
Mavi.io provides a platform that integrates retail directly into vehicle dashboards, enabling users to discover, purchase, and receive products from major retailers while on the go.
AI powered reconciliation for high-volume payments companies
B2B Marketplace for Steel Raw Materials
On-demand food delivery for Africa
Fashion resale marketplace powered by live streaming and video
A direct to consumer marketplace and influencer network for brands
Super Hyperlocal Marketplace for SMEs in Indonesia
The platform for buying, selling and managing residential construction
Where restaurants in Africa buy food supplies
B2B marketplace for construction material in Brazil.
Group buy for groceries in African cities.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
1
grants and programs matching the idea
1135
startup-relevant grants in Healthcare and bio
$598M
awarded in the sector, tracked
130
opportunities open now in the sector
- Low-cost and high efficiency DNA-based Reverse Genetics Platforms for manufacturing RNA virus products.awardhigh relevance
NIH / NCHHSTP · SBIR phase I · $279K · posted 2025-09-30
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 119 → 224 → 170 → 92 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 24 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 38 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Marketplace
- Path to 100x
- Creates a new category
- Market size
- $100B+ market
- Capital intensity
- Capital-light (software margins)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Real engineering
- Go-to-market
- Founder-led sales
- Moat
- Distribution moat
- Geography
- US first
- Regulation
- Unregulated
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-22 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.